FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a compound of formula I or a pharmaceutically acceptable salt thereof. In the formula I R1 is hydrogen; R2 is pyridinyl, where R2 optionally substituted with 1–3 R4; R3 represents phenyl, where R3 is optionally substituted with 1–5 R5; R4 independently represents C1-C6alkyl; R5 independently represents C1-C6alkyl, halogen or -(C0-C3alkyl)CF3. Invention also relates to a pharmaceutical composition, which comprises a compound of formula I and a pharmaceutically acceptable carrier, an adjuvant or vehicle, a method for treating or reducing the severity of a disease or condition responsive to inhibiting Janus kinase activity in a patient, and using a compound of formula I.
(I).
EFFECT: claimed compounds are useful as inhibitors of one or more Janus kinases.
6 cl, 1 dwg, 508 ex, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PYRAZOLOPYRIMIDINE-BASED JAK INHIBITING COMPOUNDS AND METHODS | 2010 |
|
RU2567238C2 |
| PYRAZOLPYRIMIDINE COMPOUNDS JAK INHIBITORS AND METHODS | 2009 |
|
RU2539568C2 |
| BICYCLIC DIHYDROPYRIMIDINECARBOXAMIDE DERIVATIVES AS RHO-KINASE INHIBITORS | 2017 |
|
RU2778478C2 |
| PYRAZOLE DERIVATIVES AS KALLIKREIN INHIBITORS | 2017 |
|
RU2739447C2 |
| EP4 ANTAGONISTS | 2016 |
|
RU2761341C2 |
| COMPOUNDS OF 1-CYANO-PYRROLIDINES AS USP30 INHIBITORS | 2016 |
|
RU2717238C2 |
| PYRAZOLO[1,5-A]PYRIMIDINYLCARBOXAMIDES AND THEIR USE FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS | 2017 |
|
RU2799332C2 |
| PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | 2013 |
|
RU2658006C2 |
| QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING SAME | 2011 |
|
RU2582610C2 |
| N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDE COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | 2015 |
|
RU2707870C2 |
